DanielJosephDeAngeloMD

Oncology • Boston, MA

Hematologic Oncology

Chief of the Division of Leukemia, Dana-Farber Cancer Institute Professor of Medicine, Harvard Medical School

Join to view full profile

Dr. DeAngelo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. DeAngelo's full profile

Already have an account?

Office
450 Brookline Avenue
Dana-Farber Cancer Institute
Boston, MA 02115
Phone+1 617-632-2645

Fax+1 617-632-6771

Summary

Dr. Daniel DeAngelo is an oncologist in Boston, MA. He is currently the Chief of the Division of Leukemia at the Dana-Farber Cancer Institute and Brigham and Women's Hospital. He received his medical degree from Albert Einstein College of Medicine in 1993. He completed an internship and residency at the Massachusetts General Hospital and fellowship at the Dana-Farber Cancer Institute. He specializes in the treatment of patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelydysplastic syndromes, myeloproliferative neoplams, and systemic mastocytosis. He has more than 300 publications, reviews and chapters and over 39,000 citations with a h-index of 93.

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1996 - 1999
Massachusetts General HospitalResidency, Internal Medicine, 1993 - 1996
Albert Einstein College of MedicineClass of 1993

Certifications & Licensure

FL State Medical License 2022 - Present
MA State Medical License 1995 - 2026
NH State Medical License 2024 - 2026
ME State Medical License 2023 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Start of enrollment: 1998 Aug 01
Completed
Phase 2
Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia Start of enrollment: 2005 Aug 01
Completed
Phase 2
A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) Start of enrollment: 2002 May 01
Completed
Phase 2
Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia Start of enrollment: 2000 Jan 01
Completed
Phase 1
A Study in Adults With Untreated Acute Lymphoblastic Leukemia Start of enrollment: 2002 Jun 01
Active, not recruiting
Phase 2
ALL Adult Consortium Trial: Adult ALL Trial Start of enrollment: 2007 Apr 01
Active, not recruiting
Phase 2
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia Start of enrollment: 2007 Nov 15
Completed
Phase 2
Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia Start of enrollment: 2008 Jun 01
Unknown status
Phase 1, Phase 2
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Dec 14
Completed
Phase 2
Alisertib for Acute Myeloid Leukemia Start of enrollment: 2013 Apr 01
Completed
Phase 1
A Safety Study of SGN-CD19A for Leukemia and Lymphoma Start of enrollment: 2013 Feb 01
Completed
Phase 1
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia Start of enrollment: 2013 Apr 30
Active, not recruiting
Phase 2
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL Start of enrollment: 2014 Apr 24
Completed
Phase 1
Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults Start of enrollment: 2014 Dec 01
Completed
Phase 1
A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL Start of enrollment: 2015 Oct 01
Completed
Phase 1, Phase 2
Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) Start of enrollment: 2015 Aug 21
Terminated
Phase 2
Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML Start of enrollment: 2015 Dec 01
Completed
Phase 2
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia Start of enrollment: 2017 Jun 01
Suspended
Phase 3
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL Start of enrollment: 2017 Oct 30
Recruiting
Phase 1, Phase 2
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN Start of enrollment: 2018 Jan 02
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis.
Rathnam K Venkat, Robert A Redd, Amyah C Harris, Martin J Aryee, Anna E Marneth
Blood Advances. 2024-12-10
Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemia.
Ibrahim Aldoss, Gail J Roboz, Renato Bassan, Nicolas Boissel, Daniel J DeAngelo
The Lancet. Haematology. 2024-12-01
Venetoclax plus low intensity chemotherapy for adults with acute lymphoblastic leukemia.
Marlise R Luskin, Shai Shimony, Julia H Keating, Eric S Winer, Jacqueline S Garcia
Blood Advances. 2024-11-15

Abstracts/Posters

A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-P...
Daniel J. DeAngelo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd
Daniel J. DeAngelo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic ...
Daniel J. DeAngelo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...
Daniel J. DeAngelo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Single Cell RNA-Seq Reveals Deranged Developmental Hierarchy with Coexisting Oncogenic States and Immune Evasion Programs in ETP T-ALL
Daniel J. DeAngelo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendriti...
Daniel J. DeAngelo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories
Daniel J. DeAngelo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia
Daniel J. DeAngelo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy
Daniel J. DeAngelo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelody...
Daniel J. DeAngelo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendriti...
Daniel J. DeAngelo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Pre...
Daniel J. DeAngelo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies
Daniel J. DeAngelo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Sleep Disturbance Among Patients with Myelodysplastic Syndromes and Acute Leukemia
Daniel J. DeAngelo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Management of CAR T-Cell Toxicities: Concordance and Divergence between Healthcare Providers and Expert Consensus Recommendations
Daniel J. DeAngelo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelody...
Daniel J. DeAngelo, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/7/2019
Join now to see all

Lectures

New Data and Paradigms in ALL: Insights and Applications
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with R...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Ov...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A phase III trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed/refractory acute myeloid leukemia.
2019 ASCO Annual Meeting - 6/1/2019
A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients wi...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Comprehensive Cytokine Profiling of Patients with Advanced Systemic Mastocytosis Treated with Midostaurin
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Quality of Life and Psychological Distress in Patients with Acute Myeloid Leukemia (AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
How the Experts Treat Acute Lymphocytic Leukemia: Case Discussions From Adolescent to Adult
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Press Mentions

Targeted Approaches to Systemic Mastocytosis ManagementSeptember 3rd, 2024
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)December 11th, 2022
Biotech Co.’s Shares Soar on Ph. 2 Hematology Trial ResultsJune 13th, 2022
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member